Skip to main content

Table 2 Comparison of genotype frequencies of miRNA polymorphisms between patients and controls

From: Associations between microRNA (miR-25, miR-32, miR-125, and miR-222) polymorphisms and recurrent implantation failure in Korean women

Genotypes

Controls

(n = 228)

IF ≥ 2

(n = 118)

AOR (95% CI)a

Pa

IF ≥ 3 (n = 106)

AOR (95% CI)a

Pa

IF ≥ 4 (n = 75)

AOR (95% CI)a

Pa

miR-25 rs1527423 T>C

 TT

179 (78.5)

94 (79.7)

1.000 (reference)

 

84 (79.25)

1.000 (reference)

 

57 (76.00)

1.000 (reference)

 

 TC

46 (20.2)

23 (19.5)

0.947 (0.541–1.658)

0.849

21 (19.81)

0.968 (0.542–1.728)

0.913

17 (22.67)

1.146 (0.608–2.159)

0.673

 CC

3 (1.3)

1 (0.8)

0.632 (0.065–6.169)

0.693

1 (0.94)

0.709 (0.073–6.931)

0.767

1 (1.33)

1.044 (0.106–10.249)

0.971

 Dominant (TT vs TC+CC)

  

0.927 (0.535–1.606)

0.788

 

0.952 (0.540–1.679)

0.865

 

1.139 (0.613–2.116)

0.680

 Recessive (TT+TC vs CC)

  

0.639 (0.066–6.218)

0.700

 

0.713 (0.073–6.959)

0.771

 

1.014 (0.104–9.927)

0.991

 HWE P

0.981

0.753

  

0.804

  

0.832

  

miR-32 rs7041716 C>A

 CC

187 (82.0)

94 (79.7)

1.000 (reference)

 

85 (80.19)

1.000 (reference)

 

58 (77.33)

1.000 (reference)

 

 CA

39 (17.1)

22 (18.6)

1.123 (0.629–2.004)

0.695

19 (17.92)

1.069 (0.582–1.963)

0.829

16 (21.33)

1.315 (0.683–2.530)

0.413

 AA

2 (0.9)

2 (1.7)

1.893 (0.262–13.686)

0.527

2 (1.89)

2.072 (0.286–15.003)

0.471

1 (1.33)

1.446 (0.128–16.310)

0.766

 Dominant (CC vs CA+AA)

  

1.163 (0.663–2.040)

0.600

 

1.121 (0.623–2.016)

0.704

 

1.322 (0.697–2.508)

0.392

 Recessive (CC+CA vs AA)

  

1.876 (0.260–13.511)

0.532

 

2.064 (0.286–14.894)

0.472

 

1.390 (0.124–15.610)

0.790

 HWE P

0.983

0.594

  

0.45

  

0.906

  

miR-125a rs12976445 C>T

 CC

170 (74.6)

98 (83.1)

1.000 (reference)

 

87 (82.08)

1.000 (reference)

 

63 (84.00)

1.000 (reference)

 

 CT

52 (22.8)

20 (16.9)

0.680 (0.383–1.208)

0.188

19 (17.92)

0.734 (0.408–1.321)

0.303

12 (16.00)

0.633 (0.316–1.266)

0.196

 TT

6 (2.6)

0 (0.0)

N/A

0.995

0 (0.00)

0.000 (0.000–0.000)

0.995

0 (0.00)

0.000 (0.000–0.000)

0.993

 Dominant (CC vs CT+TT)

  

0.610 (0.346–1.075)

0.087

 

0.658 (0.368–1.177)

0.158

 

0.568 (0.286–1.130)

0.107

 Recessive (CC+CT vs TT)

  

N/A

0.995

 

N/A

0.995

 

N/A

0.993

 HWE P

0.408

0.315

  

0.311

  

0.448

  

miR-222 rs34678647 G>T

 GG

133 (58.3)

62 (52.5)

1.000 (reference)

 

56 (52.83)

1.000 (reference)

 

39 (52.00)

1.000 (reference)

 

 GT

79 (34.6)

48 (40.7)

1.320 (0.825–2.112)

0.247

42 (39.62)

1.284 (0.787–2.096)

0.317

31 (41.33)

1.343 (0.775–2.327)

0.294

 TT

16 (7.0)

8 (6.8)

1.030 (0.415–2.560)

0.949

8 (7.55)

1.144 (0.457–2.859)

0.774

5 (6.67)

0.999 (0.340–2.938)

0.999

 Dominant (GG vs GT+TT)

  

1.273 (0.813–1.993)

0.291

 

1.262 (0.792–2.009)

0.327

 

1.288 (0.761–2.179)

0.346

 Recessive (GG+GT vs TT)

  

0.944 (0.391–2.279)

0.898

 

1.054 (0.435–2.553)

0.908

 

0.911 (0.321–2.589)

0.861

 HWE P

0.371

0.752

  

0.974

  

0.726

  
  1. IF, implantation failure; AOR, adjusted odds ratio; for AOR, OR adjusted by age of participants; 95% CI, 95% confidence interval; N/A, not applicable
  2. aAdjusted by age
Back to article page

Human Genomics

ISSN: 1479-7364